Tomohiro Matsushima

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

Yuji Yamamoto, Junji Matsui, Tomohiro Matsushima et al. · Vascular Cell · 2014 · 500 citations · Full text

Medicine, Oncology, Pharmacology +16

Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization

Kiyoshi Okamoto, Megumi Ikemori‐Kawada, A. Jestel et al. · ACS Medicinal Chemistry Letters · 2014 · 278 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

E7050: A dual c‐Met and VEGFR‐2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models

Takayuki Nakagawa, Osamu Tohyama, Atsumi Yamaguchi et al. · Cancer Science · 2009 · 104 citations · Full text

Medicine, Oncology, Pharmacology +17

E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling

Kazuhiko Yamada, Yusaku Hori, Satoshi Inoue et al. · Cancer Research · 2021 · 61 citations · Full text

Medicine, Oncology, Pharmacology +16

Synthetic studies of 18-membered anti-tumor macrolide, tedanolide. Computer-aided conformational design of a seco-acid derivative for efficient macrolactonization

Tomohiro Matsushima, Kiyoshi Horita, Noriyuki Nakajima et al. · Tetrahedron Letters · 1996 · 47 citations

Pharmacy, Chemistry, Medicinal Chemistry +15